Related Experiment Videos
Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia
Franck Lalloum1, Eric H Souied, Sylvie Bastuji-Garin
1Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, France.
Retina (Philadelphia, Pa.)
|December 30, 2009
Summary
Intravitreal injections of ranibizumab significantly improved visual acuity and reduced retinal thickness in patients with myopic choroidal neovascularization. This treatment shows promise for managing this condition.
Area of Science:
- Ophthalmology
- Medical Retina
- Pharmacology
Background:
- Pathologic myopia can lead to choroidal neovascularization (CNV), a major cause of vision loss.
- Myopic CNV often affects individuals of working age, necessitating effective treatment strategies.
Purpose of the Study:
- To assess the efficacy of intravitreal ranibizumab injections for treating choroidal neovascularization (CNV) secondary to pathologic myopia.
- To evaluate changes in visual acuity and retinal thickness following treatment.
Main Methods:
- A prospective case series included 32 eyes of 32 patients with myopic CNV.
- Treatment involved intravitreal injections of ranibizumab.
- Patients were monitored for best-corrected visual acuity and central retinal thickness using optical coherence tomography.
Main Results:
- A median of 3 ranibizumab injections were administered over a median follow-up of 17 months.
- Median visual acuity improved from 20/100 to 20/50 (P < 0.0001).
- Median central retinal thickness decreased from 336 µm to 233 µm (P < 0.0001), with no severe drug-related side effects.
Conclusions:
- Intravitreal ranibizumab injections demonstrated significant visual acuity improvement and reduction in retinal thickness in patients with myopic CNV.
- Further multicenter trials are warranted to confirm the safety and efficacy of this therapeutic approach.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...